EGFR and non-small cell lung carcinoma: Common to all proposed signatures, sensitivity to first generation EGFR TKIs was linked to high expression of a well-established epithelial marker CDH1, while resistance was associated with high expression of pro-mesenchymal markers vimentin (VIM) and ZEB1. The ability of these signatures to predict clinical response to EGFR TKIs was tested in cohorts that included both EGFR-mutant and EGFR-wild type NSCLC patients (Yauch et al., 2005; Kim et al., 2011).